Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven.
Department of Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, U.S.A.
Ophthalmic Plast Reconstr Surg. 2022;38(5):496-502. doi: 10.1097/IOP.0000000000002190. Epub 2022 May 3.
To review the demographics, clinical features, and response of orbital squamous cell carcinoma treated with cemiplimab.
This is a retrospective multi-institutional series. Patient characteristics, drug dosing, duration, and response to treatment were evaluated.
The study cohort consisted of 11 patients from 5 institutions. All patients received a regimen of 350 mg q 3 weeks and an average of 11.2 cycles (SD 5.8). No patient experienced significant side effects requiring treatment or cessation of cemiplimab. Complete response was achieved in 9 patients (82%) treated with cemiplimab.
Immune checkpoint inhibitors, such as cemiplimab provide a globe-sparing option for the treatment of orbital squamous cell carcinoma. It is important to consider these agents especially when orbital exenteration is the alternative.
回顾接受西普单抗治疗的眼眶鳞状细胞癌的人口统计学、临床特征和反应。
这是一项回顾性多机构研究。评估了患者特征、药物剂量、治疗持续时间和对治疗的反应。
研究队列包括来自 5 个机构的 11 名患者。所有患者均接受了 350mg q3 周的治疗方案，平均接受了 11.2 个周期（标准差为 5.8）。没有患者因需要治疗或停止西普单抗而出现明显的副作用。9 名（82%）接受西普单抗治疗的患者达到完全缓解。
免疫检查点抑制剂，如西普单抗为治疗眼眶鳞状细胞癌提供了一种保留眼球的选择。当眼眶切除术是替代方案时，特别需要考虑这些药物。
